Advanced search
Publication Cover
Future Virology Volume 2, 2007 - Issue 6
Submit an article Journal homepage
114
Views
0
CrossRef citations to date
0
Altmetric
Review

Pathobiology of Virus Glycosylation: Implications to Disease and Prospects for Treatment

David J VigerustVanderbilt University Medical Center,Department of Pediatrics,Program in Vaccine Sciences,1161 21st Avenue South, T-0107 MCN (Mailing), T-2219 MCN (Lab),Nashville,TN37232-2007,USA. Tel.: +1 615 343 8263; Fax: +1 615 936 8014; [email protected]View further author information
Pages 615-623 | Published online: 31 Oct 2007

Bibliography

  • Mondotte JA , LozachPY, AmaraA, GamarnikAV: Essential role of Dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation.J. Virol.81, 7136–7148 (2007).
  • Korber B , GaschenB, YusimK, ThakallapallyR, KesmirC, DetoursV: Evolutionary and immunological implications of contemporary HIV-1 variation.Br. Med. Bull.58, 19–42 (2001).
  • Wei X , DeckerJM, WangSet al.: Antibody neutralization and escape by HIV-1. Nature422, 307–312 (2003).
  • Land A , BraakmanI: Folding of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum.Biochimie83, 783–790 (2001).
  • Slater-Handshy T , DrollDA, FanX, Di BisceglieAM, ChambersTJ: HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing.Virology319, 36–48 (2004).
  • Meunier JC , FournillierA, ChoukhiAet al.: Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. J. Gen. Virol.80 (Pt 4), 887–896 (1999).
  • Wagner R , WolffT, HerwigA, PleschkaS, KlenkHD: Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics.J. Virol.74, 6316–6323 (2000).
  • Klenk HD , WagnerR, HeuerD, WolffT: Importance of hemagglutinin glycosylation for the biological functions of influenza virus.Virus Res.82, 73–75 (2002).
  • Baigent SJ , McCauleyJW: Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture.Virus Res.79, 177–185 (2001).
  • Tsuchiya E , SugawaraK, HongoS, MatsuzakiY, MurakiY, NakamuraK: Role of overlapping glycosylation sequons in antigenic properties, intracellular transport and biological activities of influenza A/H2N2 virus haemagglutinin. J. Gen. Virol.83, 3067–3074 (2002).
  • Tsuchiya E , SugawaraK, HongoSet al.: Effect of addition of new oligosaccharide chains to the globular head of influenza A/H2N2 virus haemagglutinin on the intracellular transport and biological activities of the molecule. J. Gen. Virol.83, 1137–1146 (2002).
  • Abe Y , TakashitaE, SugawaraK, MatsuzakiY, MurakiY, HongoS: Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin. J. Virol.78, 9605–9611 (2004).
  • Kaverin NV , RudnevaIA, IlyushinaNAet al.: Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J. Gen. Virol.83, 2497–2505 (2002).
  • Daniels R , KurowskiB, JohnsonAE, HebertDN: N-linked glycans direct the cotranslational folding pathway of influenza hemagglutinin. Mol. Cell11, 79–90 (2003).
  • Skehel JJ , WileyDC: Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin.Annu. Rev. Biochem.69, 531–569 (2000).
  • Vigerust DJ , UlettKB, BoydKL, MadsenJ, HawgoodS, McCullersJA: N-Linked glycosylation attenuates H3N2 influenza viruses.J. Virol.81, 8593–8600 (2007).
  • Deshpande KL , FriedVA, AndoM, WebsterRG: Glycosylation affects cleavage of an H5N2 influenza virus hemagglutinin and regulates virulence. Proc. Natl Acad. Sci. USA84, 36–40 (1987).
  • Zambon MC : Epidemiology and pathogenesis of influenza.J. Antimicrob. Chemother.44(Suppl. B), S3–S9 (1999).
  • Martin-Gallardo A , FleischerE, DoyleSAet al.: Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium.J. Gen. Virol.74(Pt 3), 453–458 (1993).
  • Collins PL , MottetG: Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A.J. Gen. Virol.73(Pt 4), 849–863 (1992).
  • Aguilar HC , MatreyekKA, FiloneCMet al.: N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J. Virol.80, 4878–4889 (2006).
  • Moll M , KaufmannA, MaisnerA: Influence of N-glycans on processing and biological activity of the Nipah virus fusion protein.J. Virol.78, 7274–7278 (2004).
  • Bossart KN , CrameriG, DimitrovASet al.: Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J. Virol.79, 6690–6702 (2005).
  • Oostra M , de HaanCA, de GrootRJ, RottierPJ: Glycosylation of the severe acute respiratory syndrome coronavirus triple-spanning membrane proteins 3a and M. J. Virol.80, 2326–2336 (2006).
  • Schowalter RM , SmithSE, DutchRE: Characterization of human metapneumovirus F protein-promoted membrane fusion: critical roles for proteolytic processing and low Ph.J. Virol.80(22), 10931–10941 (2006).
  • Korber B , MuldoonM, TheilerJet al.: Timing the ancestor of the HIV-1 pandemic strains. Science288, 1789–1796 (2000).
  • Fenouillet E , GluckmanJC, BahraouiE: Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1.J. Virol.64, 2841–2848 (1990).
  • Montefiori DC , RobinsonWEJr, MitchellWM: Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA85, 9248–9252 (1988).
  • Wolk T , SchreiberM: N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4–3 are indispensable for viral infectivity and resistance against antibody neutralization.Med. Microbiol. Immunol. (Berl)195, 165–172 (2006).
  • Wolk T , SchreiberM: N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4–3 are indispensable for viral infectivity and resistance against antibody neutralization.Med. Microbiol. Immunol.195, 165–172 (2006).
  • Bernstein HB , TuckerSP, HunterE, SchutzbachJS, CompansRW: Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides.J. Virol.68, 463–468 (1994).
  • Paulson JC : Glycoproteins: what are the sugar chains for?Trends Biochem. Sci.14, 272–276 (1989).
  • Burton DR : Antibodies, viruses and vaccines.Nat. Rev. Immunol.2, 706–713 (2002).
  • Sanders RW , VenturiM, SchiffnerLet al.: The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol.76, 7293–7305 (2002).
  • Manrique A , RusertP, JoosBet al.: In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J. Virol.81, 8793–8808 (2007).
  • Calarese DA , LeeHK, HuangCYet al.: Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl Acad. Sci. USA102, 13372–13377 (2005).
  • Calarese DA , ScanlanCN, ZwickMBet al.: Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science300, 2065–2071 (2003).
  • Geijtenbeek TB , van KooykY: DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr. Top Microbiol. Immunol.276, 31–54 (2003).
  • Vigerust DJ , EganBS, ShepherdVL: HIV-1 Nef mediates post-translational down-regulation and redistribution of the mannose receptor.J. Leukoc. Biol.77, 522–534 (2005).
  • Trujillo JR , RogersR, MolinaRMet al.: Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor. Proc. Natl Acad. Sci. USA104, 5097–5102 (2007).
  • Frost SD , WrinT, SmithDMet al.: Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl Acad. Sci. USA102, 18514–18519 (2005).
  • Malenbaum SE , YangD, CavaciniL, PosnerM, RobinsonJ, Cheng-MayerC: The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J. Virol.74, 11008–11016 (2000).
  • Simmonds P : Genetic diversity and evolution of hepatitis C virus – 15 years on.J. Gen. Virol.85, 3173–3188 (2004).
  • Shirato K , MiyoshiH, GotoAet al.: Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus. J. Gen. Virol.85, 3637–3645 (2004).
  • Scherret JH , MackenzieJS, KhromykhAA, HallRA: Biological significance of glycosylation of the envelope protein of Kunjin virus.Ann. NY Acad. Sci.951, 361–363 (2001).
  • Beasley DW , WhitemanMC, ZhangSet al.: Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J. Virol.79, 8339–8347 (2005).
  • Lad VJ , ShendeVR, GuptaAK, KoshyAA, RoyA: Effect of tunicamycin on expression of epitopes on Japanese encephalitis virus glycoprotein E in porcine kidney cells.Acta Virol.44, 359–364 (2000).
  • Hanna SL , PiersonTC, SanchezMD, AhmedAA, MurtadhaMM, DomsRW: N-linked glycosylation of West Nile virus envelope proteins influences particle assembly and infectivity. J. Virol.79, 13262–13274 (2005).
  • Bryant JE , CalvertAE, MesesanKet al.: Glycosylation of the Dengue 2 virus E protein at N67 is critical for virus growth in vitro but not for growth in intrathoracically inoculated Aedes aegypti mosquitoes. Virology366(2), 415–423 (2007).
  • Crabtree MB , KinneyRM, MillerBR: Deglycosylation of the NS1 protein of Dengue 2 virus, strain 16681: construction and characterization of mutant viruses.Arch Virol.150, 771–786 (2005).
  • Goffard A , CallensN, BartoschBet al.: Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol.79, 8400–8499 (2005).
  • Beyene A , BasuA, MeyerK, RayR: Influence of N-linked glycans on intracellular transport of hepatitis C virus E1 chimeric glycoprotein and its role in pseudotype virus infectivity.Virology324, 273–285 (2004).
  • Goffard A , DubuissonJ: Glycosylation of hepatitis C virus envelope proteins.Biochimie85, 295–301 (2003).
  • Falkowska E , KajumoF, GarciaE, ReinusJ, DragicT: Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization.J. Virol.81, 8072–8079 (2007).
  • Witvrouw M , FikkertV, HantsonAet al.: Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J. Virol.79, 7777–7784 (2005).
  • Williams DC, Jr., LeeJY, CaiM, BewleyCA, CloreGM: Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL free and bound to Man3GlcNAc2: structural basis for specificity and high-affinity binding to the core pentasaccharide from N-linked oligomannoside. J. Biol. Chem.280, 29269–29276 (2005).
  • Balzarini J , Van HerrewegeY, VermeireK, VanhamG, ScholsD: Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol. Pharmacol.71, 3–11 (2007).
  • O‘Keefe BR , SmeeDF, TurpinJAet al.: Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother.47, 2518–2525 (2003).
  • Balzarini J : Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?Antivir. Chem. Chemother.18, 1–11 (2007).
  • Helle F , WychowskiC, Vu-DacN, GustafsonKR, VoissetC, DubuissonJ: Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans.J. Biol. Chem.281, 25177–25183 (2006).
  • Bertaux C , DaelemansD, MeertensLet al.: Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology366(1), 40–50 (2007).
  • Keyaerts E , VijgenL, PannecouqueCet al.: Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res.75, 179–187 (2007).
  • van der Meer FJ , de HaanCA, SchuurmanNMet al.: Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture. Antiviral Res.76, 21–29 (2007).
  • Romanelli F , SmithKM, HovenAD: Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity.Curr. Pharm. Des.10, 2643–2648 (2004).
  • Boelaert JR , SperberK, PietteJ: Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea.AIDS Res. Hum. Retroviruses15, 1241–1247 (1999).
  • Sperber K , LouieM, KrausTet al.: Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin. Ther.17, 622–636 (1995).
  • Paton NI , AboulhabJ: Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.HIV Med.6, 13–20 (2005).
  • Naarding MA , BaanE, PollakisG, PaxtonWA: Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology4, 6 (2007).
  • Vincent MJ , BergeronE, BenjannetSet al.: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J.2, 69 (2005).
  • De Clercq E : Potential antivirals and antiviral strategies against SARS coronavirus infections.Expert Rev. Anti Infect. Ther.4, 291–302 (2006).
  • Keyaerts E , VijgenL, MaesP, NeytsJ, Van RanstM: In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine.Biochem. Biophys. Res. Commun.323, 264–268 (2004).
  • Di Trani L , SavarinoA, CampitelliLet al.: Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol. J.4, 39 (2007).
  • Ooi EE , ChewJS, LohJP, ChuaRC: In vitro inhibition of human influenza A virus replication by chloroquine.Virol. J.3, 39 (2006).
  • Savarino A , Di TraniL, DonatelliI, CaudaR, CassoneA: New insights into the antiviral effects of chloroquine. Lancet Infect. Dis.6, 67–69 (2006).
  • Chapel C , GarciaC, BartoschBet al.: Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. J. Gen. Virol.88, 1133–1143 (2007).
  • Tanaka Y , KatoJ, KoharaM, GalinskiMS: Antiviral effects of glycosylation and glucose trimming inhibitors on human parainfluenza virus type 3.Antiviral Res.72, 1–9 (2006).
  • Wu SF , LeeCJ, LiaoCL, DwekRA, ZitzmannN, LinYL: Antiviral effects of an iminosugar derivative on flavivirus infections.J. Virol.76, 3596–3604 (2002).
  • Balzarini J : The alpha(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wildtype and mutant HIV-1 strains containing glycan deletions in gp120.FEBS Lett581, 2060–2064 (2007).
  • Hart ML , SaifuddinM, SpearGT: Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin.J. Gen. Virol.84, 353–360 (2003).
  • Dwek RA , ButtersTD, PlattFM, ZitzmannN: Targeting glycosylation as a therapeutic approach. Nat. Rev. Drug Discov.1, 65–75 (2002).
  • Furmanek A , HofsteengeJ: Protein C-mannosylation: facts and questions.Acta Biochim. Pol.47, 781–789 (2000).
  • Falzarano D , KrokhinO, Van DomselaarGet al.: Ebola sGP–the first viral glycoprotein shown to be C-mannosylated. Virology (Epub ahead of print) (2007).
  • Cambi A , de LangeF, van MaarseveenNMet al.: Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic cells. J. Cell Biol.164, 145–155 (2004).
  • Cambi A , FigdorCG: Dual function of C-type lectin-like receptors in the immune system.Curr. Opin. Cell Biol.15, 539–546 (2003).
  • Reading PC , MillerJL, AndersEM: Involvement of the mannose receptor in infection of macrophages by influenza virus.J. Virol.74, 5190–5197 (2000).
  • Nguyen DG , HildrethJE: Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages.Eur. J. Immunol.33, 483–493 (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.